Showing results (481-490 of 661) with videos related to
Sort By:
Pageof 67
Cell Reports|September 8, 2015
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXRLinara Gabitova, Diana Restifo, Andrey Gorin, et al.Journal of Lipid Research|December 8, 2009
Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infectionRonald W Clark, David Cunningham, Yang Cong, et al.The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Science (New York, N.Y.)|February 24, 2018
Patient-derived organoids model treatment response of metastatic gastrointestinal cancersGeorgios Vlachogiannis, Somaieh Hedayat, Alexandra Vatsiou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.Journal of Gastric Cancer|July 7, 2017
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient DataCharles S Fuchs, Kei Muro, Jiri Tomasek, et al.JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.Pageof 67